CW2IP2: Imaging and Diagnostic Assessments

Launched by UNIVERSITY OF PENNSYLVANIA · Oct 10, 2023

Keywords

ClinConnect Summary

The CW2IP2 clinical trial is studying specific brain changes related to conditions known as tauopathies, which include diseases like Parkinson's Disease and Frontotemporal Dementia. Researchers are focused on developing new imaging techniques that can help identify the presence of certain proteins in the brain, which are markers of these conditions. The study involves several universities working together, and they will recruit participants aged 40 to 85 years, both men and women, to help gather important data.

To be eligible for this trial, participants need to have a confirmed diagnosis of one of the targeted conditions or be healthy controls. It’s important that they can provide informed consent, meaning they understand what the study involves and agree to participate. Participants will undergo imaging tests and may also agree to donate their brain for research after they pass away, which is a requirement for those with tauopathies. Throughout the study, participants can expect to have regular visits and assessments, helping researchers gain insights that could improve diagnosis and treatment options in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Participants: Patients in all cohorts will range from 40 to 85 yrs and will be both male and female.
• • Participants must be informed of the investigational nature of this study and be willing to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures. Participants who are deemed unable to provide informed consent must have a designated Legally Authorized Representative(LAR) present for consent and a Study Partner to accompany them to study visits. The LAR and the Study Partner may be the same person.
• • Clinical diagnoses for each cohort will be determined by consensus committee for diagnostic agreement (PD, MSA, PSP, FTD or Healthy control)
• Exclusion Criteria:
• • Females who are pregnant or breast feeding at the time of screening will be excluded
• • Forms of parkinsonism other than PD, PSP and MSA as defined above
• • Major psychiatric disorder (e.g. schizophrenia or bipolar disorder)
• • History of significant or ongoing alcohol abuse or substance abuse or dependence based on medical record review or self-reported
• • Contraindications or Inability to tolerate imaging, arterial line or IV placement or blood draw procedures in the opinion of an investigator or treating physician
• • Implanted medical device or other contraindication to MRI
• • Any current medical condition, illness, or disorder as assessed by medical record review and/or self-reported that is considered by a physician or investigator to be a condition that could compromise participant safety or successful participation in the study
• • Refusal to consent to brain donation (except for HC cohort). All non-HC participants must agree to postmortem brain donation..